ArticleNature communications2024
Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Concomitant HPV Vaccination and HPV Screening for Rapid Elimination of HPV Infection and Cervical Cancer in Sweden
Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Clinicopathological features and survival outcomes of HPV-independent versus HPV-associated cervical adenocarcinoma: a Systematic Review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Efficacy of human papillomavirus vaccines in the prevention of male genital diseases: a systematic review.BJU international · 2025Pooled it
- Inferred functional microbiome features are associated with clinical trajectories of low-grade cervical lesions.BMC microbiology · 2026Article
- Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy.Experimental & molecular medicine · 2026Review
- Challenges and possible solutions towards reaching global cervical cancer elimination.EClinicalMedicine · 2026Review
- Analyzing and forecasting global cervical cancer burden based on WHO's elimination strategy: insights and projections from a 1990-2021 global burden of disease (GBD) study covering 204 countries and territories.Journal of advanced research · 2026Article
- Predicting optimal impact interventions in the post-HPV vaccination world.International journal of cancer · 2026Review
- From evidence to action: the IARC's role in strengthening cancer prevention and early detection.Journal of the National Cancer Institute. Monographs · 2026Review
- Article
- Human Papillomavirus Screening: Design and Targeting of Human Papillomavirus Genotypes.Current topics in microbiology and immunology · 2026Review
- Comparative performance of hrHPV testing and PAX1/ZNF671 methylation in triaging women with abnormal cytology: a study of paired urine, vaginal and cervical scrape samples.Frontiers in oncology · 2026Article
- Inequalities in HPV vaccine offer among Italian regions: Analysis of regional prevention plans.Human vaccines & immunotherapeutics · 2025Article
- Knowledge of human papillomavirus and self-sampling, including vaccination practices among female students in Free State, South Africa.Cancer causes & control : CCC · 2025Article
- Review
- Temporal Trends in Cervical Human Papillomavirus Prevalence Among Females in Xiamen, China (2016-2023): Cross-Sectional Study.JMIR public health and surveillance · 2025Article
- Natural history of liver fluke infection underpins epidemiological patterns of biliary cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Human Papillomavirus Vaccination Coverage Estimates Among the Primary Target Cohort (9-14-Year-Old Girls) in the World (2010-2024).Vaccines · 2025Article
- Molecular Screening for Cervical Cancer.Genes · 2025Review
- Accelerating HPV-related cancer elimination - a meeting report.BMC proceedings · 2025Article
- PAX1/SOX1 gene methylation as a detection and triage method for triage of high risk HPV-Positive women in cervical cancer screening.Gynecologic oncology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
HPV vaccination with concomitant HPV-based screening of young women has been proposed for faster cervical cancer elimination. We describe the baseline results of a population-based trial of this strategy to reduce the incidence of HPV. All 89,547 women born 1994-1999 and resident in the capital region of Sweden were personally invited to concomitant HPV vaccination and HPV screening with 26,125 women (29.2%) enrolled between 2021-05-03 and 2022-12-31. Baseline HPV genotyping of cervical samples from the study participants finds, compared to pre-vaccination prevalences, a strong decline of HPV16 and 18 in birth cohorts previously offered vaccination, some decline for cross-protected HPV types but no decline for HPV types not targeted by vaccines. Our dynamic transmission modelling predicts that the trial could reduce the incidence of high-risk HPV infections among the 1994-1998 cohorts by 62-64% in 3 years. Baseline results are prevalences of HPV infection, validated transmission model projections, and power estimates for evaluating HPV incidence reductions at follow-up (+/-0.1% with 99.9% confidence). In conclusion, concomitant HPV vaccination and HPV screening appears to be a realistic option for faster cervical cancer elimination. Clinicaltrials.gov identifier: NCT04910802; EudraCT number: 2020-001169-34.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.